Cancer Genetics to Present at the 2021 BioConnect Virtual Conference Hosted by H.C. Wainwright
07 Janvier 2021 - 10:05PM
Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging
leader in novel drug discovery techniques, announced today that Jay
Roberts, Chief Executive Officer, will present at the 2021
BioConnect Virtual Conference hosted by H.C. Wainwright. Registered
attendees can access the recorded presentation on-demand (24x7) for
the duration of the conference.
Conference Date: |
January 11-14, 2021 (Monday-Thursday) |
On-Demand Starts: |
6:00am ET - Monday, January 11, 2021 |
On-Demand Ends |
9:00pm ET- Thursday, January 14, 2021 |
Registration: |
https://hcwevents.com/bioconnect/ |
Mr. Roberts will highlight the Company's recent
transformational business strategy, discuss near-term events
including the Company’s proposed merger with StemoniX, Inc., and
the broader corporate vision of the Company going forward.
CGIX will be available for virtual 1:1 meetings
both during and after the BioConnect Conference. Please contact
Jennifer K. Zimmons, Ph.D. jzimmons@zimmonsic.com 917.214.3514 for
scheduling.
ABOUT CANCER GENETICS
Through its vivoPharm subsidiary, Cancer
Genetics offers proprietary preclinical test systems supporting
drug discovery programs, valued by the pharmaceutical industry,
biotechnology companies and academic research centers. The Company
is focused on precision and translational medicine to drive drug
discovery and novel therapies. vivoPharm specializes in conducting
studies tailored to guide therapeutic development, starting from
compound libraries and ending with a comprehensive set of in vitro
and in vivo data and reports, as needed for Investigational New
Drug filings. vivoPharm operates in The Association for Assessment
and Accreditation of Laboratory Animal Care International (AAALAC)
accredited and GLP compliant audited facilities. For more
information, please visit www.cancergenetics.com.
For more information, please visit or follow CGI
at:
Internet: www.cancergenetics.com
Twitter: @Cancer_Genetics
Forward Looking Statements:
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. All statements pertaining to Cancer Genetics
Inc.’s expectations regarding future financial and/or operating
results, and potential for our services, future revenues or growth,
or the potential for future strategic transactions in this press
release constitute forward-looking statements.
Any statements that are not historical fact
(including, but not limited to, statements that contain words such
as “will,” “believes,” “plans,” “anticipates,” “expects,”
“estimates”) should also be considered to be forward-looking
statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, risks inherent in our
ability to satisfy all closing conditions to the merger with
StemoniX, Inc. and realize the expected benefits therefrom, our
attempts to adapt to the global coronavirus pandemic, our attempts
to achieve profitability by increasing sales of our pre-clinical
services, maintain our existing customer base and avoid
cancellation of customer contracts or discontinuance of trials, our
attempts to raise capital to meet our liquidity needs, market and
other conditions, and other risks discussed in the Cancer Genetics,
Inc. Form 10-K for the year ended December 31, 2019 and Form 10-Q
for the quarter ended June 30, 2020, along with other filings with
the Securities and Exchange Commission. These forward-looking
statements speak only as of the date hereof. Cancer Genetics, Inc.
disclaims any obligation to update these forward-looking
statements.
Investor Contacts: Jennifer K. Zimmons. Ph.D.
Investor Relations Zimmons International Communications, Inc.
Email: jzimmons@zimmonsic.com Phone: +1.917.214.3514
Cancer Genetics (NASDAQ:CGIX)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Cancer Genetics (NASDAQ:CGIX)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024